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Background: Nanoparticles have been extensively investigated for targeted delivery of anticancer drugs. Since the
folate receptor is universally over-expressed on the tumor cell membrane, folic acid is often used to modify the fate
of nanoparticles in biologicals.
Methods: To fabricate targetable nanoparticles, folic acid was conjugated to a pullulan backbone and
poly(DL-lactide-co-glycolide) (PLGA) (abbreviated as FAPuLG) was conjugated. KB cells and NIH3T3-cell-bearing mice
were prepared to prove folate receptor targeting of FAPuLG nanoparticles.
Results and discussion: Nanoparticles of FAPuLG copolymer that self-assembled in water were small with
diameters <200 nm. Doxorubicin (DOX) as a model drug was incorporated into the FAPuLG nanoparticles
that were used to treat folate receptor over-expressing KB human carcinoma cells. Fluorescence microscopy
revealed that DOX-incorporated FAPuLG nanoparticles induced strong red fluorescence in the KB cells in the
absence of folic acid. However, fluorescence intensity was decreased by blocking folate receptors. Antitumor
activity of FAPuLG nanoparticles against KB cells in vitro was also decreased by blocking folate receptors. In
animal study using near-infrared dye-conjugated FAPuLG nanoparticles, fluorescence intensity was significantly
higher at KB solid tumor than that of NIH3T3.
Conclusions: The results indicate that FAPuLG nanoparticles can target the folate receptor of tumor cells.
FAPuLG nanoparticles are a promising candidate for active targeting of anticancer agents.
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Nanoparticle-based targeted drug delivery systems have
been extensively investigated for biomedical applications
[1-4]. The unique features of nanoscale carriers are their
huge surface area versus volume, ease of surface modifica-
tion, prolonged circulation in the blood through avoidance
of the reticuloendothelial system, and small size that fa-
cilitates specific interaction with cell surface receptors,
enabling the targeting of specific cells or tissues having* Correspondence: pik96@chonnam.ac.kr; hclee@chonnam.ac.kr
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in any medium, provided the original work is pdisease in the specific organs [1,2,5-10]. Furthermore,
tumor-specific targeting of nanoparticles allows the killing
of tumor cells selectively without harm to healthy tissues
or cells [6-8].
Since nanoparticles themselves do not possess tumor
specificity, various kinds of tumor-specific ligand such as
endothelial growth-factor-related peptide [5], hyaluronic
acid [6], galactose [7], folic acid [8], monoclonal anti-
body [9], and transferrin [10] have been used to bestow
tumor-specific drug targeting of nanoparticles. Among
them, the folate receptor is over-expressed in virtually
all types of tumor cells, while being barely detectable in
healthy tissues and cells [11-13]. Folic-acid-anchored
nanoparticles have tumor-specific targeting of anticancerpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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that doxorubicin (DOX)-encapsulated nanoparticles hav-
ing folic acid on the particle surface were remarkably ef-
ficient for the regression of tumor growth and reduction
of toxicity compared to free DOX or plain nanoparticles
[13]. Furthermore, nanoparticles having folic acid as a
targeting moiety facilitate accumulation of anticancer
agents in tumors [14].
In this study, folic-acid-conjugated pullulan-g-poly(DL-
lactide-co-glycolide) (PLGA) (abbreviated as FAPuLG) co-
polymers were synthesized for targeted delivery of a model
anticancer agent (DOX) to tumor cells. The advantages of
pullulan include biocompatibility, immuno-neutrality, and
numerous functional hydroxyl groups [15,16]. Hence,
pullulan can be used as a drug-carrying material and its
derivatives, such as pullulan/PLGA graft copolymer, can
be considered as an ideal vehicle for fabrication of drug-
targeting carriers.
We previously reported that PuLG copolymer can self-
assemble in an aqueous environment to form small
nanospheres <100 nm in diameter, which are useful as a
drug-delivery carrier [17]. Physicochemical properties of
nanoparticles of FAPuLG were studied and their target-
ing potential was assessed using KB tumor cells in vitro.
Methods
Materials
Pullulan (Mn 67,500) and PLGA 5005 (Mn 8,200) were
purchased from Wako Pure Chemical Industries, Osaka,
Japan. Folic acid, N,N′-dicyclohexyl carbodiimide (DCC)
and 4-(N,N-dimethylamino)pyridine (DMAP) were pur-
chased from Aldrich Chemical (St. Louis, MO, USA).
DOX HCl and triethyleamine (TEA) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Spectra/Pro™ dialysis
membranes with a molecular weight cutoff (MWCO) of
6,500 g/mol were purchased from Spectrum Laboratories
(Rancho Dominguez, CA, USA). Sulfo-cyanine 5 carbox-
ylic acid was purchased from Lumiprobe Co. (Florida,
USA). Dichloromethane (DCM) and dimethyl sulfoxide
(DMSO) of high-performance liquid chromatography
grade were dried with CaH2 then distilled prior to use. 1H
nuclear magnetic resonance (NMR) spectra were recorded
in deuterated solvents (DMSO-d6) at a concentration of
30 mg/0.6 ml using a model AMX-300 apparatus (Bruker,
Billerica, MA, USA).
Synthesis of folic-acid-conjugated copolymer
Pullulan (675 mg) was dissolved in DMSO (15 ml) for
3 h. Folic acid was dissolved in DMSO (5 ml) with a
1.1 equivalent amount of DCC and DMAP for 30 min.
Folic acid solution was added into the pullulan solution
and stirred for 24 h in a nitrogen atmosphere. The result-
ing solution was filtered to remove by-products and di-
alyzed against deionized water for 3 days, followed bylyophilization. The synthesized folic acid-pullulan (FA-
PU) conjugates were analyzed with NMR. FA-Pu-PLGA
(abbreviated as FAPuLG) copolymers were synthesized as
follows. Three hundred milligrams of FA-PU and 182 mg
of PLGA were dissolved separately in dried DMSO. A 1.2
equivalent amount DCC in DMSO solution was added to
the PLGA/DMSO solution, which was stirred for 30 min
to activate the carboxyl group of the PLGA. The resulting
solution was added to the pullulan/DMSO solution con-
taining 1.2 equivalent amount DMAP, and the reaction
was allowed to continue at room temperature for 24 h. The
reaction mixture was filtered to remove the by-products
and exhaustively dialyzed against deionized water for 3
days. The dialyzed solution was lyophilized for 3 days, and
the solid product was precipitated three times in DCM to
remove unreacted PLGA and dried in a vacuum oven for
2 days. The substitution degree of folic acid and PLGA
was calculated from molecular weight of pullulan and
PLGA [17]. PuLG copolymer was synthesized as described
previously [17]. The number-average molecular weight
(Mn) of synthesized copolymers was analyzed using 1H
NMR spectroscopy. The molecular weight (M.W.) of pull-
ulan and PLGA was analyzed using gel permeation chro-
matography as reported previously [17]. The weight average
M.W. (Mw), Mn, and polydispersity of pullulan were
67,500, 62,400, and 1.081, respectively. The Mw, Mn,
and polydispersity of PLGA were 8,200, 5,800, and
1.41, respectively.
Near-infrared absorption dye (NIR dye) conjugation
was performed as follows: 20 mg of FAPuLG copolymer
was dissolved in dry DMSO. To this solution, 1 mg of
sulfo-cyanine 5 carboxylic acid with equivalent mole of
DCC and DMAP was added and then stirred for 12 h in
the room temperature. After that, resulting solution was
dialyzed to remove unreacted dye with exchange of
water at intervals of 3 h. The dialysis procedure was
continued until that dye was not detected. Dye in the di-
alyzed solution was detected with UV spectrophotometer
(UV-1601 UV-VIS spectrophotometer, Shimadzu, Kyoto,
Japan) at 642 nm. To evaluate conjugation yield, 3 mg of
dye-conjugated polymer was dissolved in DMSO and
then the contents of the dye in the polymer were mea-
sured with the UV spectrophotometer. For a blank test,
polymer without dye was used. Dye contents (%, w/w) =
[(Weight of dye in the polymer/total weight of poly-
mer) × 100]. The content of the dye in the polymer was
approximately 3.2% (w/w).
Preparation of nanoparticles
Twenty milligrams of PuLG or FAPuLG was dissolved in
3 ml of DMSO. Five milligrams of DOX was separately
dissolved in 1 ml of DMSO with trace amounts of TEA
and added to the polymer/DMSO solution. The resulting
solution was slowly added dropwise to 10 ml of deionized
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tubing was put into 1 l of deionized water. During dialysis,
DOX-loaded nanoparticles formed and organic solvent
was removed. Dialysis was continued for 12 h with
changes of the water every 2 h. The resulting solution was
analyzed or lyophilized. To determine drug contents, 5
mg of lyophilized nanoparticles were dissolved in DMSO,
and the absorbance was measured using a UV spectropho-
tometer (UV-1601 UV-VIS spectrophotometer, Shimadzu,
Kyoto, Japan) at 479 nm. Drug contents (%, w/w) were cal-
culated as (amount of DOX in the nanoparticles/weight of
nanoparticles) × 100.
Characterization of nanoparticles
Nanoparticle morphology was performed using trans-
mission electron microscopy (TEM) using a JEM-2000
FX II microscope (JEOL, Tokyo, Japan). The diameter of
the nanoparticles was measured with a model DLS-7000
dynamic laser scattering apparatus (Otsuka Electronics
Company, Osaka, Japan). A sample solution prepared
by dialysis was used to determine particle size (concen-
tration 1 mg/ml). The critical association concentration
(CAC) of nanoparticles was evaluated with a model
RF-5301 fluorescence spectrofluorophotometer (Shimadzu,
Tokyo, Japan) as described previously [17]. PuLG or
FAPuLG nanoparticles in the absence of a drug were
prepared as described above. Polymer (40 mg) was dis-
solved in DMSO (5 ml) and dialyzed against deionized
water for up to 2 days. The nanoparticle suspension was
adjusted to various concentrations. The CAC of nanopar-
ticles was estimated using pyrene as a hydrophobic probe.
To prepare sample solutions, a known amount of pyrene
in acetone was added to each of a series of 20-ml vials,
and the acetone was evaporated. The final concentration
of pyrene was 6.0 × 10−7 M. To each vial, 10 ml of various
concentrations of the nanoparticle suspensions was added,
and the solutions were heated for 3 h at 65°C. Equilibra-
tion of the pyrene and the PuLG nanoparticles was
achieved by allowing the solutions to cool overnight at
room temperature. The fluorescence excitation spectra
were measured at an emission wavelength of 390 nm. Ex-
citation and emission bandwidths were 1.5 and 1.5 nm,
respectively.
Drug release study
Drug release from nanoparticles was carried out at
physiological solutions. Five milligrams of nanoparticle
solid was reconstituted into 5 ml of deionized water and
then introduced into a dialysis tubing. The sealed dialy-
sis tubing was added to a 50-ml Falcon tube containing
40 ml of phosphate-buffered saline (PBS) solutions (pH
7.4, 0.1 M). These tubes were placed in a shaking incu-
bator with a stirring speed of 100 rpm at 37°C. At spe-
cific times, the medium was sampled for analysis of drugconcentration. Afterwards, the entire medium was re-
placed with fresh medium to prevent drug saturation.
The concentration of drug released was measured using
the aforementioned ultraviolet spectrophotometer at
479 nm.
Cell culture
KB human oral squamous carcinoma cells and NIH3T3
mouse fibroblast cells were obtained from the Korean Cell
Line Bank (KCLB, Seoul, Korea) and maintained with
DMEM medium supplemented with 10% fetal bovine
serum (FBS) and 1% antibiotics in a 5% CO2 incubator op-
erating at 37°C.
Targetability of nanoparticles for folate receptor of KB
cell
To study targetability of nanoparticles against the folate
receptor of tumor cells, KB cells were seeded onto cover
glass in 6-well plates and cultured overnight in a 5%
CO2 incubator (37°C) with RPMI 1640 media (supple-
mented with 10% FBS and 1% antibiotics). Cells were
washed with PBS (pH 7.4, 0.1 M) and treated with 5 μg/ml
of DOX or nanoparticles for 1 h. DOX was dissolved in
DMSO and then diluted at least 100 times with folic
acid free-RPMI1640 medium. Lyophilized nanoparticles
were carefully reconstituted into folic acid free-RPMI1640
medium. To prove targetability of nanoparticles, KB
cells were pre-treated with folic acid (5 mM) 1 h before
addition of nanoparticles. After 1 h, cells were washed
with PBS and treated with 4% paraformaldehyde. Cells
were washed again with PBS and fixed by immobilization
solution (ImmuMount, Thermo Electron Corporation,
Pittsburgh, PA). These cells were observed by confocal
laser scanning microscopy (CLSM) using a TCS-SP2
microscope (Leica, Wetzlar, Germany). Flow cytometry
analysis of cells was also performed to assess targetability
of nanoparticles. KB cells were seeded at a density of 1 ×
106 cells in 6-well plates and incubated overnight. Cells
were treated with DOX or nanoparticles as described
above. After 1 h, cells were harvested and analyzed with a
flow cytometer. An excitation wavelength at 488 nm and
emission wavelength at 522 nm were used to observe the
fluorescence intensity of DOX.
In vitro antitumor activity
Nanoparticle antitumor activity against KB cells were
assessed by an established viability assay based on 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) in vitro. KB cells (3 × 104) were seeded in 96-well
plates and incubated overnight in a 5% CO2 incubator
at 37°C. DOX or nanoparticles (DOX concentration,
50 μg/ml) were added to wells in the absence or presence
of folic acid and then incubated for 4 h. The medium was
replaced with a serum-free medium in the absence of folic
Figure 1 Synthesis scheme of FAPuLG copolymer (a) 1H NMR spectra of FA-PU (b), PuLG (c), and FAPuLG (d) conjugates.
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Table 1 Characterization of FAPuLG copolymer
Polymer Theoretical ratioa Experimental ratioc
FA PUa PLGA M.W. FA PU PLGA
Pullulan - 100 - 67,500* 100
FAPu 1 10 100 - 86,244b 570 mg 9.88 100
FAPu 2 20 100 - 105,411b 630 mg 35.8 100
PLGA - - 100 8,200*
PuLG - 100 1.2 108,684b 250 mg 0 100 1.27
106,696c
FAPuLG 1 10 100 1.2 146,267b 260 mg 6.00 100 1.46
151,453c
FAPuLG 2 20 100 1.2 127,244b 210 mg 21.5 100 1.78
139,918c
*M.W. was evaluated from M.W. of pullulan and PLGA as reported previously
[17]. aThe feeding molar ratio of FA and PLGA versus 100 glucose unit of PU;
bMn - theoretical value; cMn was analyzed with NMR.
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the 96-well plates and incubated for 4 h. The formazan
crystals formed in living cells were solubilized with a so-
dium dodecyl sulfate (SDS)/HCl solution (SDS, 10% w/v;
HCl 0.1 N), and the absorbance was determined at 570
nm using an automated computer-linked microplate
reader (Molecular Devices, Sunnyvale, CA, USA).
In vivo fluorescence imaging of NIH3T3 and
KB-tumor-bearing mouse
1 × 106 KB cells and 1 × 106 NIH3T3 cells were im-
planted onto the right side and left side of the back of
nude BALb/C mice (5 weeks, 20 g), respectively. Three
weeks later, NIR-dye-conjugated nanoparticles (dose: 20
mg/kg, injection volume: 100 μl) were injected intraven-
ously (i.v.) into the tail vein of the mouse. At specific
time intervals, the trace of nanoparticles in the mouse
was observed with Maestro™ 2 small animal imaging in-
strument (Cambridge Research and Instruments, Inc.,
Woburn, MA, USA). After nanoparticle administration
(48 h), the mice were sacrificed to observe organ distri-
bution of nanoparticles, and each organ of the mice was
also observed with Maestro™ 2 small animal imaging in-
strument. All animal studies were performed under guide-
lines of the Committee of Care and Use of Laboratory
Animals of Chonnam National University.
Statistical data analysis
The results are expressed as the means of three parallel
experiments ± standard deviation. Statistical analysis of
the results was performed using the t-test with p < 0.05
as the minimal level of significance.
Results
Characterization of FAPuLG copolymer
Figure 1a depicts the synthesis scheme of the FAPuLG
copolymer. Folic acid was conjugated to hydroxyl groups
of pullulan using carbodiimide chemistry. Specific peaks
of pullulan appeared between 3.0 ~ 5.8 ppm, and specific
peaks of folic acid appeared at 6.5 ~ 9.0 ppm (Figure 1b).
The substitution degree of folic acid against 100 glucose
units of pullulan backbone was 9.88 and 35.8, respect-
ively (Table 1). PLGA was also conjugated to FA-PU
conjugates (Figure 1). The methylene proton of PLGA
was appeared at 1.5 ppm (Figure 1d). These results indi-
cated that FAPuLG copolymers were successively syn-
thesized. Furthermore, PuLG copolymer without folic
acid was synthesized for comparison and its characteris-
tic peaks of pullulan and PLGA (Figure 1c). The substi-
tution degree of folic acid and PLGA was calculated by
1H NMR spectra from known M.W.s of pullulan and
PLGA [17]. Table 1 shows the characteristics of FAPuLG
copolymer. The substitution degree of PLGA for PuLG,FAPuLG-1, and FAPuLG-2 was 1.27, 1.46, and 1.78,
respectively.
Characterization of nanoparticles
To make nanoparticles, FAPuLG was dissolved in DMSO
and then added dropwise to deionized water. Organic
solvent was removed by dialysis method. The average
diameter of the formed nanoparticles was consist-
ently <200 nm (Figure 2a, Table 2). Particle sizes of
FAPuLG were slightly larger than PuLG, suggesting that
the folic acid moiety may increase their average diameter.
Furthermore, PuLG and FAPuLG nanoparticles were
spherical (Figure 2b). Their sizes were not significantly dif-
ferent from the results of particle size measurement. Since
PuLG and FAPuLG are amphiphilic polymers composed
of the hydrophilic domain of pullulan and hydrophobic
domain of PLGA, formation of nanoparticles occurred by
self-aggregation process in the aqueous environment.
To study the self-assembly of nanoparticles, fluorescence
spectroscopy measured CAC using pyrene as a fluores-
cence probe. The fluorescence spectra showed a red shift
according to the increase of copolymer concentration, in-
dicating that the self-assembly of the copolymer was
formed in water, and then, pyrene was preferentially parti-
tioned into the core of the nanoparticles (Figure 3a,c).
A flat region and a sigmoid change in the crossover re-
gion were observed at low concentrations of copolymer
(Figure 3d,f). These crossover regions were known to
be the CAC of the copolymer. The CAC of PuLG,
FAPuLG-1, and FAPuLG-2 was 0.026 g/l, 0.011 g/l, and
0.01 g/l, respectively. DOX was used as a model anticancer
drug. DOX was incorporated into the PuLG and FAPuLG
nanoparticles. The results are summarized in Table 2.
When DOX was incorporated into the nanoparticles, sizes
were increased significantly compared to empty nanoparti-
cles. The drug release kinetics was shown in Figure 4. The
Figure 2 Typical particle size (a) and TEM image (b) of FAPuLG-1 nanoparticles.
Lee et al. Nanoscale Research Letters  (2015) 10:43 Page 6 of 11drug release rate was relatively fast until 36 h, after
which release was continuous. The nanoparticles having
larger diameter and higher drug contents induced a slower
release rate of drugs.
Folate-receptor-mediated endocytosis and targeting of
FAPuLG nanoparticles
To test receptor-mediated delivery of drugs, DOX was
used as a model drug because it has strong red fluores-
cence and can be used instead of a fluorescence marker.
DOX-incorporated FAPuLG nanoparticles were studied
using KB cells. Representative fluorescence images and
flow cytometry results are depicted in Figure 5a,b, re-
spectively. KB cells revealed strong red color when DOX
or DOX-incorporated FAPuLG nanoparticles were treated,
indicating that DOX or DOX-incorporated FAPuLG nano-
particles were entered into the tumor cells (Figure 5a).
However, red fluorescence was decreased significantly












PuLG 123.1 20 6.8
FAPuLG-1 168.1 20 7.2
FAPuLG-2 173.1 20 7.4with folic acid. These results indicated that nanoparticles
of FAPuLG nanoparticles entered into the cells through
folate-receptor-mediated endocytosis. Flow cytometry
analysis also supported these results (Figure 5b), indicating
that fluorescence intensity of KB cells was increased when
DOX or DOX-incorporated nanoparticles were treated.
Fluorescence intensity was decreased by the blocking of
the folate receptor. Cell viability was checked to test
receptor-mediated delivery of drug, and then, nanoparti-
cles can selectively kill the tumor cells (Figure 6). Cell via-
bility of FAPuLG nanoparticle treatment did not differ
with the DOX values. However, viability of cell popula-
tions treated with FAPuLG nanoparticles increased when
the folate receptor was blocked with folic acid. However,
cell viability with DOX treatment was not significantly
changed by blocking of folate receptor. These results indi-
cated that FAPuLG nanoparticles can target the folate re-
ceptor of KB cells and selectively kill tumor cells.
For in vivo biodistribution imaging of FAPuLG nano-
particles, FAPuLG was conjugated with water-soluble
NIR dye. To investigate KB tumor cell specificity of NIR-
dye-conjugated FAPuLG, KB cells (folate-receptor-positive
tumor cell) and NIH3T3 cells (folate-receptor-negative
mouse fibroblast cells) were simultaneously implanted to
the right side and left side of the nude mice as shown in
Figure 7. Fluorescence intensity was continuously strong
in the right side of the mice until 48 h. Even though
FAPuLG nanoparticles were also considerably accumu-
lated in the liver at organ distribution, FAPuLG nanoparti-
cles in the solid mass of KB tumor were significantly
higher than the solid mass of NIH3T3. These results indi-
cated that FAPuLG nanoparticles have specificity for the
KB cells and targetability against folate receptor of the
tumor cells.
Figure 3 Fluorence excitation and plots of intensity ratios. Fluorescence excitation of pyrene (6.0 × 10 − 7 M) vs. the concentration of PuLG
(a), FAPuLG-1 (b), and FAPuLG-2 (c) nanoparticles in distilled water (λem = 390 nm). Plots of the intensity ratios, I338/I335, from the pyrene
excitation spectra vs. log c of the PuLG (d), FAPuLG-1 (e), and FAPuLG-2 (f) nanoparticles in distilled water. Each point was derived from
the fluorescence spectra curve. The arrows indicate the signal changes in the crossover region.
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Targeted drug delivery using nanoparticles is a promising
strategy for treatment of tumor cells [1-13]. Since tumor
cells generally over-express various kinds of receptors
on the cell membrane, receptor-mediated delivery ofbioactive agents is an ideal way to maximize antitumor
activity and minimize the unwanted side effect of antican-
cer drugs. Nanoparticles are an ideal candidate for these
purposes because the target ligand can easily be decorated
on the large surface area of nanoparticles. Nanoparticles
Figure 4 DOX release from PuLG and FA-PuLG nanoparticles.
Figure 6 Cytotoxicity of DOX-incorporated FAPuLG nanoparticles
against KB cells (*, ** = p < 0.05). KB cells were pre-treated with folic
acid 1 h before drug treatment, and then, cells were exposed to 50
μg/ml of DOX or nanoparticles for 4 h. Twenty-four hours later, viable
cells were determined using the MTT assay.
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diameter), which enables nanoparticle virus-like behavior
and passive targeting in the human body [18]. Various
target ligands have been developed to decorate the sur-
faces of colloidal carriers and nanoparticles [5-10]. Among
them, folic acid is often selected for tumor targeting of
nanoparticulate anticancer drugs because most of tumorFigure 5 Confocal laser scanning microscope images (a) and flow cytometric analysis (b). KB cells were treated with DOX or FAPuLG-2
nanoparticles. For blocking of the folate receptor of tumor cells, folic acid was pre-treated 1 h before drug or nanoparticle treatment.
Figure 7 The NIR fluorescence imaging study. BALb/C nude mouse bearing an NIH3T3 (left side) and KB tumor (right side) was used.
NIR-dye-conjugated nanoparticles (20 mg/kg) were intravenously injected via the tail vein of the mouse. The major organs of the mice
were taken 48 h after administration. The data shown as the mean ± SD (n = 4).
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[8]. Then, targeting to the folate receptor of tumor cells
enables nanoparticles to concentrate anticancer drugs in
tumor cells and to avoid healthy cells. Zwicke et al. intro-
duced the folate receptor for active targeting of cancer
cells using various kinds of nanomaterials [8]. Folic-acid-
decorated nanomaterials can be used to various kinds of
cancer therapies, such as cancer chemotherapy, cancer
imaging, and/or imaging of circulating cancer cells in the
human body [8,18,19].
In this study, we used pullulan for conjugation of folic
acid and fabrication of nanocarriers of the anticancer
drug, DOX. Pullulan, which is a water-soluble, neutral,
linear polysaccharide, has properties of biocompatibil-
ity and biodegradability. These attributes have been exploited
in the extensive biomedical use of pullulan as a nanoma-
terial [17,20-22]. Since pullulan is highly water-soluble,
copolymerization with PLGA endowed amphiphilic prop-
erties to copolymers, i.e., pullulan backbone acts as ahydrophilic domain and PLGA acts as a hydrophobic do-
main [17]. PLGA can form a hydrophobic drug container
while pullulan is normally exposed on the surface of
nanoparticles. Furthermore, folic acid conjugated with
a pullulan backbone also can be exposed on the surface of
nanoparticles due to amphiphilicity of FAPuLG copolymer
and then used as a targeting ligand for cancer targeting.
Figure 4 depicts the self-assembly property of the FAPuLG
copolymer in an aqueous environment and the resulting
very low CAC values. PuLG and FAPuLG nanoparticles
have small particle sizes <200 nm, which allow drug tar-
geting to specific organs and tissues, avoidance of the re-
ticuloendothelial system, prolonged blood circulation,
and virus-like behavior [23]. FAPuLG nanoparticles
showed targetability against the folate receptor of KB cells
(Figure 5), and antitumor activity of DOX was controlled
by folate-receptor-mediated drug delivery, indicating that
nanoparticles of FAPuLG can be used to deliver an anti-
cancer agent specifically to the folate receptor of tumor
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conjugate can target the folate receptor of KB cells, with
the IC50 of folate-polymer conjugate-coated liposomes be-
ing twofold lower than polymer liposomes [24]. We also
obtained positive results from the anticancer activity of
FAPuLG nanoparticles (Figure 6). DOX-incorporated nano-
particles retained still cytotoxicity against tumor cells even
though the folate receptor was blocked. These results might
be due to the passive diffusion of drug or nanoparticles
into the cells. However, cell viability with treatment of
FAPuLG nanoparticles in the presence of folic acid was
increased 20% higher than that in the absence of folic
acid, indicating that FAPuLG is a promising candidate
for active targeting of the folate receptor of tumor cells.
Furthermore, we demonstrated that FAPuLG nanoparti-
cles have targetability against KB tumor as shown in
Figure 7. Fluorescence imaging study of animals using
NIR-dye-conjugated nanoparticles showed that fluores-
cence intensity was significantly higher in the solid mass
of KB tumor cells than in the solid mass of NIH3T3.
These results indicated that FAPuLG nanoparticles can
specifically target the folic acid receptor of tumor cells.
Shen et al. also reported that folic-acid-decorated nano-
photosensitizer was highly sensitive for targeting of the
folate receptor of KB cells but not for NIH3T3 normal
cells [25]. Furthermore, they also described that the viabil-
ity of NIH3T3 normal cells was not affected by the treat-
ment of nanoparticles regardless of folic acid decoration
while viability of KB cancer cells was sensitively decreased
according to the presence of folic acid on the nanoparticle
surface. Ultimately, folic acid decoration onto the nano-
particles efficiently enhances drug targeting against cancer
cell and tumor tissue in vitro/in vivo. We suggest FAPuLG
nanoparticles as an ideal candidate for tumor targeting.
Conclusions
In conclusion, we synthesized FAPuLG copolymer and
folic-acid-decorated nanoparticles for active tumor target-
ing. Nanoparticles of FAPuLG copolymer have a small
diameter (<200 nm) and targetability to the folate receptor
of KB cells. We suggest that FAPuLG copolymer nanopar-
ticles are promising vehicles for drug targeting.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SJL carried out fabrication and characterization of nanoparticles, drug release
experiment, and cell culture experiment. YHS carried out synthesis and
characterization of polymers. JSO and YIJ participated in the fluorescence
imaging study using animals. IKP provided basic idea for this study and
participated in the organization of results. HCL controlled overall progress of
experiment and participated in the designing of this study and wrote this
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This research was supported by Leading Foreign Research Institute
Recruitment Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education, Science and Technology(MEST)
(2011-0030034).
Author details
1Department of Biomedical Sciences, Chonnam National University Medical
School, Gwangju 501-746, Korea. 2Biomedical Research Institute, Pusan
National University Hospital, Pusan 602-739, Republic of Korea. 3Department
of Microbiology, Chonnam National University Medical School, Gwangju
501-746, Korea.
Received: 18 November 2014 Accepted: 23 December 2014
References
1. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle
and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci.
2012;48:416–27.
2. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug
delivery systems. Pharmacol Rep. 2012;64(5):1020–37.
3. Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of
medical nanoparticles. Int J Nanomedicine. 2012;7:5577–91.
4. Murthy SK. Nanoparticles in modern medicine: state of the art and future
challenges. Int J Nanomedicine. 2007;2(2):129–41.
5. Studenovsky M, Pola R, Pechar M, Etrych T, Ulbrich K, Kovar L, et al. Polymer
carriers for anticancer drugs targeted to EGF receptor. Macromol Biosci.
2012;12(12):1714–20.
6. Jeong YI, Kim DH, Chung CW, Yoo JJ, Choi KH, Kim CH, et al. Self-assembled
nanoparticles of hyaluronic acid/poly(DL-lactide-co-glycolide) block copolymer.
Colloids Surf B: Biointerfaces. 2012;90:28–35.
7. Jeong YI, Seo SJ, Park IK, Lee HC, Kang IC, Akaike T, et al. Cellular
recognition of paclitaxel-loaded polymeric nanoparticles composed of poly
(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer
endcapped with galactose moiety. Int J Pharm. 2005;296:151–61.
8. Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active
targeting of cancer nanotherapeutics. Nano Rev. 2012;3:18496.
9. Qin JM, Yin PH, Li Q, Sa ZQ, Sheng X, Yang L, et al. Anti-tumor effects of
brucine immuno-nanoparticles on hepatocellular carcinoma. Int J
Nanomedicine. 2012;7:369–79.
10. Wang W, Zhou F, Ge L, Liu X, Kong F. Transferrin-PEG-PE modified
dexamethasone conjugated cationic lipid carrier mediated gene
delivery system for tumor-targeted transfection. Int J Nanomedicine.
2012;7:2513–22.
11. Zhang H, Cai Z, Sun Y, Yu F, Chen Y, Sun B. Folate-conjugated β-cyclodextrin
from click chemistry strategy and for tumor-targeted drug delivery. J Biomed
Mater Res A. 2012;100:2441–9.
12. Yue Y, Eun JS, Lee MK, Seo SY. Synthesis and characterization of G5 PAMAM
dendrimer containing daunorubicin for targeting cancer cells. Arch Pharm
Res. 2012;35:343–9.
13. Gao F, Li L, Liu T, Hao N, Liu H, Tan L, et al. Doxorubicin loaded silica
nanorattles actively seek tumors with improved anti-tumor effects.
Nanoscale. 2012;4:3365–72.
14. Zhao P, Wang H, Yu M, Liao Z, Wang X, Zhang F, et al. Paclitaxel loaded
folic acid targeted nanoparticles of mixed lipid-shell and polymer-core:
in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2012;81:248–56.
15. Yuen S. Pullulan and its applications. Process Biochem. 1974;9:7–9.
16. Jeanes A. Dextrans and pullulans: industrially significant. ACS Symp Ser.
1977;45:284–98.
17. Jeong YI, Na HS, Oh JS, Choi KC, Song CE, Lee HC. Adriamycin release from
self-assembling nanospheres of poly(DL-lactide-co-glycolide)-grafted pullulan.
Int J Pharm. 2006;322:154–60.
18. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al.
Accumulation of sub-100 nm polymeric micelles in poorly permeable
tumours depends on size. Nat Nanotechnol. 2011;6:815–23.
19. Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. In vivo
magnetic enrichment and multiplex photoacoustic detection of circulating
tumour cells. Nat Nanotechnol. 2009;4:855–60.
20. Jung SW, Jeong YI, Kim YH, Kim SH. Self-assembled polymeric nanoparticles
of poly(ethylene glycol) grafted pullulan acetate as a novel drug carrier.
Arch Pharm Res. 2004;27:562–9.
21. Kim IS, Oh IJ. Preparation and characterization of stearic acid-pullulan
nanoparticles. Arch Pharm Res. 2010;33:761–7.
Lee et al. Nanoscale Research Letters  (2015) 10:43 Page 11 of 1122. Sawada S, Akiyoshi K. Nano-encapsulation of lipase by self-assembled
nanogels: induction of high enzyme activity and thermal stabilization.
Macromol Biosci. 2010;10:353–8.
23. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and
pharmaceutical applications. Adv Drug Deliv Rev. 2003;55:403–19.
24. Watanabe K, Kaneko M, Maitani Y. Functional coating of liposomes using a
folate- polymer conjugate to target folate receptors. Int J Nanomedicine.
2012;7:3679–88.
25. Shen X, Li S, Li L, Yao SQ, Xu QH. Highly efficient, conjugated-polymer-based
nano-photosensitizers for selectively targeted two-photon photodynamic
therapy and imaging of cancer cells. Chemistry. 2014;21:2214–21.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
